Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lisa Giscombe"'
Publikováno v:
SAGE Open Medical Case Reports, Vol 9 (2021)
In an era of fragmented medical care, concurrent clinical features that ultimately lead to a unified diagnosis may not be prioritized appropriately. We present a case of a 64-year-old woman referred to hematology clinic for anemia, with recent memory
Externí odkaz:
https://doaj.org/article/a11c7d56ac474b828d3daebf3a06e3c7
Publikováno v:
Case Reports in Oncological Medicine, Vol 2019 (2019)
Pembrolizumab and other immunotherapies now play a prominent role in the treatment of metastatic colon cancer. Clinicians have achieved significant response rates even in heavily pretreated patients, particularly those with mismatched repair deficien
Externí odkaz:
https://doaj.org/article/2c830d645eb048c48e10d2c89ee7521d
Autor:
Andre DeSouza, Ritesh Rathore, Lisa Giscombe, Toufic Tannous, Shiva Kumar Reddy Mukkamalla, Matthew J Keating, Nishitha Reddy
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(8)
Background Androgen deprivation therapy (ADT) remains a standard of care in metastatic prostate cancer. Recent prospective trials have explored addition of chemotherapy to ADT. We retrospectively examined overall survival in metastatic prostate cance
Publikováno v:
SAGE Open Medical Case Reports
SAGE Open Medical Case Reports, Vol 9 (2021)
SAGE Open Medical Case Reports, Vol 9 (2021)
In an era of fragmented medical care, concurrent clinical features that ultimately lead to a unified diagnosis may not be prioritized appropriately. We present a case of a 64-year-old woman referred to hematology clinic for anemia, with recent memory
Autor:
Shiva Kumar Reddy Mukkamalla, Andre Desouza, Nishitha Reddy, Lisa Giscombe, Ritesh Rathore, Matthew Keating
Publikováno v:
Journal of Clinical Oncology. 36:e17046-e17046
e17046Background: ADT remains the standard of care in treatment of mPC. Two key prospective trials over the past few years have implored addition of chemotherapy to ADT. We assessed overall surviva...
Publikováno v:
Journal of Clinical Oncology. 36:324-324
324 Background: Androgen deprivation therapy (ADT) remains a standard of care in the treatment of locally advanced prostate cancer. But thanks to a few key trials (STAMPEDE, CHAARTED, and LATITUDE) reported within the past three years, docetaxel and